[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS64575B1 - Novi heterociklični derivati i njihove upotrebe - Google Patents

Novi heterociklični derivati i njihove upotrebe

Info

Publication number
RS64575B1
RS64575B1 RS20230629A RSP20230629A RS64575B1 RS 64575 B1 RS64575 B1 RS 64575B1 RS 20230629 A RS20230629 A RS 20230629A RS P20230629 A RSP20230629 A RS P20230629A RS 64575 B1 RS64575 B1 RS 64575B1
Authority
RS
Serbia
Prior art keywords
heterocyclic derivatives
novel heterocyclic
novel
derivatives
heterocyclic
Prior art date
Application number
RS20230629A
Other languages
English (en)
Inventor
Pil Su Ho
Dong Oh Yoon
Sun Young Han
Won Il Lee
Jung Sook Kim
Woul Seong Park
Sung Oh Ahn
Hye Jung Kim
Original Assignee
C&C Res Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Res Lab filed Critical C&C Res Lab
Publication of RS64575B1 publication Critical patent/RS64575B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RS20230629A 2011-09-30 2012-09-28 Novi heterociklični derivati i njihove upotrebe RS64575B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110100369 2011-09-30
KR20120033444 2012-03-30
EP18180710.8A EP3461825B1 (en) 2011-09-30 2012-09-28 Novel heterocyclic derivatives and their uses

Publications (1)

Publication Number Publication Date
RS64575B1 true RS64575B1 (sr) 2023-10-31

Family

ID=47996667

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20230629A RS64575B1 (sr) 2011-09-30 2012-09-28 Novi heterociklični derivati i njihove upotrebe
RS20181171A RS57854B1 (sr) 2011-09-30 2012-09-28 Novi heterociklični derivati i njihove upotrebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20181171A RS57854B1 (sr) 2011-09-30 2012-09-28 Novi heterociklični derivati i njihove upotrebe

Country Status (26)

Country Link
US (1) US9586959B2 (sr)
EP (2) EP3461825B1 (sr)
JP (1) JP6031107B2 (sr)
KR (1) KR101800749B1 (sr)
CN (1) CN103889986B (sr)
AR (1) AR088085A1 (sr)
AU (1) AU2012316912B9 (sr)
BR (1) BR112014007645A2 (sr)
CA (1) CA2848154C (sr)
CY (1) CY1121292T1 (sr)
DK (2) DK2760865T3 (sr)
ES (2) ES2687693T3 (sr)
FI (1) FI3461825T3 (sr)
HR (2) HRP20230893T1 (sr)
HU (2) HUE062842T2 (sr)
LT (2) LT3461825T (sr)
MX (1) MX355795B (sr)
PL (2) PL2760865T3 (sr)
PT (2) PT3461825T (sr)
RS (2) RS64575B1 (sr)
RU (1) RU2628074C2 (sr)
SG (1) SG11201400484RA (sr)
SI (2) SI2760865T1 (sr)
TR (1) TR201814710T4 (sr)
TW (1) TWI551600B (sr)
WO (1) WO2013048214A2 (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2807599T3 (es) 2013-07-02 2021-02-23 Syngenta Participations Ag Heterociclos bi- o tricíclicos activos como plaguicidas con sustituyentes que contienen azufre
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN106187793A (zh) * 2016-01-26 2016-12-07 赵鸣 5‑氨基酮戊酸及其衍生物的盐化合物和应用
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
US10905675B2 (en) 2016-12-14 2021-02-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of pruritus
KR102070265B1 (ko) * 2017-01-26 2020-01-28 한국화학연구원 신규한 [1,2,4]트리아졸로[4,3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018153373A1 (zh) 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr抑制剂及其应用
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商C&C新藥研究所 雜環衍生物及其用途
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
AU2021273744A1 (en) 2020-05-19 2022-12-08 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
TW202317568A (zh) 2021-06-22 2023-05-01 丹麥商理奧藥品公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺半琥珀酸鹽之新穎結晶形式
TW202423429A (zh) 2022-09-29 2024-06-16 韓商Jw製藥公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺之鹽及結晶形式之製備方法以及新穎的結晶形式
TW202428578A (zh) * 2022-09-29 2024-07-16 韓商Jw製藥公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺之新穎結晶型
TW202425977A (zh) * 2022-09-30 2024-07-01 韓商Jw製藥公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺單琥珀酸鹽之新穎結晶型
US12122775B1 (en) 2024-01-16 2024-10-22 King Faisal University Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors
US12129252B1 (en) 2024-02-15 2024-10-29 King Faisal University Pyrrolo[2,3-c][2,6]naphthyridine-8-carboxylic acids as CK2 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
US5070086A (en) 1987-12-23 1991-12-03 Schering Corporation Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds
CN1285834A (zh) * 1997-11-11 2001-02-28 小野药品工业株式会社 稠合吡嗪化合物
DE69940808D1 (de) * 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
JP2000319277A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
CA2520251A1 (en) * 2003-03-27 2004-10-07 Pfizer Products Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
WO2009068246A2 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
PL2268618T3 (pl) * 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
AU2009291719A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN100580335C (zh) * 2008-09-11 2010-01-13 艾欧史密斯(中国)热水器有限公司 承压式太阳能热水器
ES2550101T3 (es) 2008-12-17 2015-11-04 Merck Patent Gmbh Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
US7928105B2 (en) 2009-01-23 2011-04-19 Takeda Pharmaceutical Company Limited Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2509983B1 (en) * 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
LT3461825T (lt) 2023-08-25
EP3461825A1 (en) 2019-04-03
TWI551600B (zh) 2016-10-01
US9586959B2 (en) 2017-03-07
PL2760865T3 (pl) 2018-12-31
TR201814710T4 (tr) 2019-01-21
TW201321381A (zh) 2013-06-01
EP3461825B1 (en) 2023-06-07
MX355795B (es) 2018-04-30
AU2012316912A8 (en) 2014-04-10
JP6031107B2 (ja) 2016-11-24
CA2848154A1 (en) 2013-04-04
MX2014003042A (es) 2014-05-28
HUE062842T2 (hu) 2023-12-28
HRP20181310T1 (hr) 2018-10-19
AR088085A1 (es) 2014-05-07
PT3461825T (pt) 2023-09-11
CA2848154C (en) 2020-04-28
AU2012316912A1 (en) 2014-03-20
ES2954303T3 (es) 2023-11-21
DK2760865T3 (en) 2018-10-08
RU2628074C2 (ru) 2017-08-14
SG11201400484RA (en) 2014-10-30
AU2012316912B2 (en) 2017-04-20
EP2760865B1 (en) 2018-07-11
LT2760865T (lt) 2018-09-25
ES2687693T3 (es) 2018-10-26
DK3461825T3 (da) 2023-08-14
EP2760865A2 (en) 2014-08-06
CY1121292T1 (el) 2020-05-29
SI2760865T1 (sl) 2018-10-30
WO2013048214A3 (en) 2013-05-23
BR112014007645A2 (pt) 2017-04-18
US20140315888A1 (en) 2014-10-23
RU2014115478A (ru) 2015-11-10
EP2760865A4 (en) 2015-03-18
HUE040374T2 (hu) 2019-03-28
RS57854B1 (sr) 2018-12-31
KR101800749B1 (ko) 2017-11-24
SI3461825T1 (sl) 2023-11-30
AU2012316912B9 (en) 2017-04-27
WO2013048214A2 (en) 2013-04-04
PL3461825T3 (pl) 2023-10-30
HRP20230893T1 (hr) 2023-11-24
CN103889986A (zh) 2014-06-25
FI3461825T3 (fi) 2023-08-17
CN103889986B (zh) 2017-07-21
PT2760865T (pt) 2018-11-05
KR20140090984A (ko) 2014-07-18
JP2014531458A (ja) 2014-11-27

Similar Documents

Publication Publication Date Title
HRP20181310T1 (hr) Novi heterociklički derivati i njihova uporaba
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1198475A1 (en) Heterocyclic compounds and uses thereof
HK1198443A1 (en) Heterocyclic compounds and uses thereof
HK1193561A1 (zh) 雜環化合物和其用途
IL227664A0 (en) New heterocyclic histories
HK1198433A1 (en) N-acyldipeptide derivatives and their uses n-
HK1207069A1 (en) Heterocyclic compounds and uses thereof
IL222288A0 (en) Heterocyclic compounds and their uses
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL233311A0 (en) History of heteroarylpiperidine and piperazine as fungicides
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
AP3611A (en) Heterocyclic compounds and their uses
EP2782571A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF